Literature DB >> 21314614

Novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase: covalent modification of NAD-binding site by aromatic thiols.

K A Chernorizov1, J L Elkina, P I Semenyuk, V K Svedas, V I Muronetz.   

Abstract

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, EC 1.2.1.12) is a glycolytic enzyme catalyzing the formation of 1,3-diphosphoglycerate from glyceraldehyde-3-phosphate and inorganic phosphate. In cooperation with E3 ubiquitin-kinase Siah1, GAPDH directly participates in the apoptotic death of neurons in Parkinson's disease. Potential GAPDH inhibitors were screened in silico, and three compounds with high affinity to the NAD-binding site and theoretically capable of forming a disulfide bond with amino acid residue Cys149 were found among cysteine and glutathione derivatives. The inhibitory effect of these compounds was tested on GAPDH from rabbit muscles using isothermal calorimetry and kinetic methods. As a result of experimental screening, we selected two compounds that inhibit GAPDH by forming disulfide bonds with the Cys149 residue in the enzyme active site. Since Cys149 is the key residue not only for the catalyzed reaction, but also for interaction with Siah1, the compounds can be assumed to inhibit the formation of the proapoptotic complex GAPDH-Siah1 and therefore have potential effect against Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21314614     DOI: 10.1134/s0006297910120047

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  4 in total

1.  Functional interplay among thiol-based redox signaling, metabolism, and ferroptosis unveiled by a genetic variant of TP53.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-14       Impact factor: 11.205

2.  Properties of substances inhibiting aggregation of oxidized GAPDH: Data on the interaction with the enzyme and the impact on its intracellular content.

Authors:  Vladimir F Lazarev; Alina D Nikotina; Pavel I Semenyuk; Diana B Evstafyeva; Elena R Mikhaylova; Vladimir I Muronetz; Maxim A Shevtsov; Anastasia V Tolkacheva; Anatoly V Dobrodumov; Alexey L Shavarda; Irina V Guzhova; Boris A Margulis
Journal:  Data Brief       Date:  2016-02-27

Review 3.  Theory and applications of covalent docking in drug discovery: merits and pitfalls.

Authors:  Hezekiel Mathambo Kumalo; Soumendranath Bhakat; Mahmoud E S Soliman
Journal:  Molecules       Date:  2015-01-27       Impact factor: 4.411

4.  Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser.

Authors:  Keerthana Gnanapradeepan; Julia I-Ju Leu; Subhasree Basu; Thibaut Barnoud; Madeline Good; Joyce V Lee; William J Quinn; Che-Pei Kung; Rexford Ahima; Joseph A Baur; Kathryn E Wellen; Qin Liu; Zachary T Schug; Donna L George; Maureen E Murphy
Journal:  Elife       Date:  2020-11-10       Impact factor: 8.140

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.